Ranolazine in chronic total occlusion percutaneous coronary intervention
We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).PMID:38691399 | DOI:10.25270/jic/24.00059 (Source: The Journal of Invasive Cardiology)
Source: The Journal of Invasive Cardiology - May 1, 2024 Category: Cardiology Authors: Michaella Alexandrou Deniz Mutlu Athanasios Rempakos Ahmed Al Ogaili James W Choi Paul Poommipanit Khaldoon Alaswad Mir Babar Basir Rhian Davies Farouc A Jaffer Phil Dattilo Lorenzo Azzalini Nazif Aygul Niranjan Reddy Brian K Jefferson Sevket Gorgulu Jaik Source Type: research
Challenging situation of coronary artery anomaly associated with ischemia and/or risk of sudden death
World J Cardiol. 2024 Apr 26;16(4):173-176. doi: 10.4330/wjc.v16.i4.173.ABSTRACTCoronary artery anomaly is known as one of the causes of angina pectoris and sudden death and is an important clinical entity that cannot be overlooked. The incidence of coronary artery anomalies is as low as 1%-2% of the general population, even when the various types are combined. Coronary anomalies are practically challenging when the left and right coronary ostium are not found around their normal positions during coronary angiography with a catheter. If there is atherosclerotic stenosis of the coronary artery with an anomaly and percutaneo...
Source: World Journal of Cardiology - May 1, 2024 Category: Cardiology Authors: Shigenori Ito Source Type: research
Ranolazine in chronic total occlusion percutaneous coronary intervention
We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).PMID:38691399 | DOI:10.25270/jic/24.00059 (Source: The Journal of Invasive Cardiology)
Source: The Journal of Invasive Cardiology - May 1, 2024 Category: Cardiology Authors: Michaella Alexandrou Deniz Mutlu Athanasios Rempakos Ahmed Al Ogaili James W Choi Paul Poommipanit Khaldoon Alaswad Mir Babar Basir Rhian Davies Farouc A Jaffer Phil Dattilo Lorenzo Azzalini Nazif Aygul Niranjan Reddy Brian K Jefferson Sevket Gorgulu Jaik Source Type: research
Challenging situation of coronary artery anomaly associated with ischemia and/or risk of sudden death
World J Cardiol. 2024 Apr 26;16(4):173-176. doi: 10.4330/wjc.v16.i4.173.ABSTRACTCoronary artery anomaly is known as one of the causes of angina pectoris and sudden death and is an important clinical entity that cannot be overlooked. The incidence of coronary artery anomalies is as low as 1%-2% of the general population, even when the various types are combined. Coronary anomalies are practically challenging when the left and right coronary ostium are not found around their normal positions during coronary angiography with a catheter. If there is atherosclerotic stenosis of the coronary artery with an anomaly and percutaneo...
Source: World Journal of Cardiology - May 1, 2024 Category: Cardiology Authors: Shigenori Ito Source Type: research
Ranolazine in chronic total occlusion percutaneous coronary intervention
We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).PMID:38691399 | DOI:10.25270/jic/24.00059 (Source: The Journal of Invasive Cardiology)
Source: The Journal of Invasive Cardiology - May 1, 2024 Category: Cardiology Authors: Michaella Alexandrou Deniz Mutlu Athanasios Rempakos Ahmed Al Ogaili James W Choi Paul Poommipanit Khaldoon Alaswad Mir Babar Basir Rhian Davies Farouc A Jaffer Phil Dattilo Lorenzo Azzalini Nazif Aygul Niranjan Reddy Brian K Jefferson Sevket Gorgulu Jaik Source Type: research
Three-Year Clinical Outcomes With the Cilotax Dual Drug-Eluting Stent vs Everolimus-Eluting Stents in Patients With Acute Myocardial Infarction
CONCLUSION: In patients with acute myocardial infarction who underwent percutaneous coronary intervention, use of the Cilotax stent was associated with higher rates of target lesion revascularization, target vessel revascularization, and stent thrombosis than were everolimus-eluting stents. Use of the Cilotax dual drugeluting stent should be avoided in the treatment of myocardial infarction.PMID:38686684 | DOI:10.14503/THIJ-23-8271 (Source: Texas Heart Institute Journal)
Source: Texas Heart Institute Journal - April 30, 2024 Category: Cardiology Authors: HyeYon Yu Jihun Ahn Byoung Geol Choi Soohyung Park Dong Oh Kang Cheol Ung Choi Seung-Woon Rha Myung Ho Jeong Source Type: research
Three-Year Clinical Outcomes With the Cilotax Dual Drug-Eluting Stent vs Everolimus-Eluting Stents in Patients With Acute Myocardial Infarction
CONCLUSION: In patients with acute myocardial infarction who underwent percutaneous coronary intervention, use of the Cilotax stent was associated with higher rates of target lesion revascularization, target vessel revascularization, and stent thrombosis than were everolimus-eluting stents. Use of the Cilotax dual drugeluting stent should be avoided in the treatment of myocardial infarction.PMID:38686684 | DOI:10.14503/THIJ-23-8271 (Source: Texas Heart Institute Journal)
Source: Texas Heart Institute Journal - April 30, 2024 Category: Cardiology Authors: HyeYon Yu Jihun Ahn Byoung Geol Choi Soohyung Park Dong Oh Kang Cheol Ung Choi Seung-Woon Rha Myung Ho Jeong Source Type: research
Three-Year Clinical Outcomes With the Cilotax Dual Drug-Eluting Stent vs Everolimus-Eluting Stents in Patients With Acute Myocardial Infarction
CONCLUSION: In patients with acute myocardial infarction who underwent percutaneous coronary intervention, use of the Cilotax stent was associated with higher rates of target lesion revascularization, target vessel revascularization, and stent thrombosis than were everolimus-eluting stents. Use of the Cilotax dual drugeluting stent should be avoided in the treatment of myocardial infarction.PMID:38686684 | DOI:10.14503/THIJ-23-8271 (Source: Texas Heart Institute Journal)
Source: Texas Heart Institute Journal - April 30, 2024 Category: Cardiology Authors: HyeYon Yu Jihun Ahn Byoung Geol Choi Soohyung Park Dong Oh Kang Cheol Ung Choi Seung-Woon Rha Myung Ho Jeong Source Type: research
Three-Year Clinical Outcomes With the Cilotax Dual Drug-Eluting Stent vs Everolimus-Eluting Stents in Patients With Acute Myocardial Infarction
CONCLUSION: In patients with acute myocardial infarction who underwent percutaneous coronary intervention, use of the Cilotax stent was associated with higher rates of target lesion revascularization, target vessel revascularization, and stent thrombosis than were everolimus-eluting stents. Use of the Cilotax dual drugeluting stent should be avoided in the treatment of myocardial infarction.PMID:38686684 | DOI:10.14503/THIJ-23-8271 (Source: Texas Heart Institute Journal)
Source: Texas Heart Institute Journal - April 30, 2024 Category: Cardiology Authors: HyeYon Yu Jihun Ahn Byoung Geol Choi Soohyung Park Dong Oh Kang Cheol Ung Choi Seung-Woon Rha Myung Ho Jeong Source Type: research
Prognostic impact of heart failure admission in survivors of acute myocardial infarction
ConclusionsUtilizing real-world data of the contemporary percutaneous coronary intervention era from the Japan Acute Myocardial Infarction Registry database, this study demonstrates that the heart failure admission of AMI survivors was significantly associated with higher all-cause mortality rates. (Source: ESC Heart Failure)
Source: ESC Heart Failure - April 30, 2024 Category: Cardiology Authors: Satoshi Takeuchi,
Satoshi Honda,
Kensaku Nishihira,
Sunao Kojima,
Misa Takegami,
Yasuhide Asaumi,
Mike Saji,
Jun Yamashita,
Kiyoshi Hibi,
Jun Takahashi,
Yasuhiko Sakata,
Morimasa Takayama,
Tetsuya Sumiyoshi,
Hisao Ogawa,
Kazuo Kimura,
Satos Tags: Original Article Source Type: research
Impact of Polyvascular Disease in Patients undergoing unprotected Left Main Percutaneous Coronary Intervention
Percutaneous coronary intervention (PCI) has demonstrated its safety and efficacy in treating left main coronary artery disease (LM-CAD) in select patients. Polyvascular disease (PolyVD) is associated with adverse events in all-comers with CAD. However, there is little data examining the interplay between PolyVD and LM-PCI, which we sought to investigate in a retrospective single-center study. We included patients undergoing unprotected LM-PCI at a tertiary center from 2012-2019. The patient population was stratified based on the presence or absence of PolyVD (i.e. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 30, 2024 Category: Cardiology Authors: Benjamin Bay, Raman Sharma, Anastasios Roumeliotis, David Power, Samantha Sartori, Jonathan Murphy, Birgit Vogel, Kenneth F Smith, Angelo Oliva, Amit Hooda, Joseph Sweeny, George Dangas, Annapoorna Kini, Prakash Krishnan, Samin K Sharma, Roxana Mehran Source Type: research
A Simple Bleeding Risk Score for the Complex Elderly Patient
Coronary artery disease (CAD) is a leading global cause of death worldwide, and in an aging society, the burden of percutaneous coronary intervention (PCI) in the elderly population is increasing.(1) An important feature that distinguishes this cohort is the significant increase in the likelihood of experiencing bleeding and ischemic events.(2) Given the comparable prognostic significance of both bleeding and ischemic events(3), the selection of the appropriate intensity and duration of antiplatelet therapy assumes a crucial role from a clinical perspective. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - April 30, 2024 Category: Cardiology Authors: Fiorenzo Simonetti, Adnan Kastrati Tags: Editorial Source Type: research
Impact of Sex Differences on Clinical Outcomes in Patients Following Primary Revascularization for Acute Myocardial Infarction - Insights From the Japanese Nationwide Registry
CONCLUSIONS: Within this nationwide cohort, women had worse clinical outcomes following AMI than men. However, these sex-related differences in outcomes diminished after adjusting for age. In addition, CKD was significantly associated with all-cause mortality in both sexes.PMID:38684394 | DOI:10.1253/circj.CJ-23-0966 (Source: Circulation Journal)
Source: Circulation Journal - April 29, 2024 Category: Cardiology Authors: Tomoya Hoshi Mitsuaki Sawano Shun Kohsaka Hideki Ishii Tetsuya Amano Toshiharu Takeuchi Jun Takahashi Daigo Hiraya Hiroaki Watabe Tomoko Ishizu Ken Kozuma Source Type: research
Impact of Sex Differences on Clinical Outcomes in Patients Following Primary Revascularization for Acute Myocardial Infarction - Insights From the Japanese Nationwide Registry
CONCLUSIONS: Within this nationwide cohort, women had worse clinical outcomes following AMI than men. However, these sex-related differences in outcomes diminished after adjusting for age. In addition, CKD was significantly associated with all-cause mortality in both sexes.PMID:38684394 | DOI:10.1253/circj.CJ-23-0966 (Source: Circulation Journal)
Source: Circulation Journal - April 29, 2024 Category: Cardiology Authors: Tomoya Hoshi Mitsuaki Sawano Shun Kohsaka Hideki Ishii Tetsuya Amano Toshiharu Takeuchi Jun Takahashi Daigo Hiraya Hiroaki Watabe Tomoko Ishizu Ken Kozuma Source Type: research
Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis
ConclusionOverall, our findings suggest that bivalirudin may be a more efficacious intervention than heparin for reducing certain adverse events in patients with STEMI undergoing primary PCI. (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - April 29, 2024 Category: Cardiology Source Type: research
